Novo Nordisk A/S (NVO) — closed signal from July 10, 2025
Partial Published before the outcome was known, scored automatically when the window closed on October 8, 2025.
Predicted vs. what happened
What happened
Reached 17% of the predicted growth at its peak, without hitting the target.
The thesis — published July 10, 2025
After a recent 12% dip caused by worries about a lost Canadian patent, the company behind Ozempic and Wegovy is still growing fast and earning more on each sale thanks to new factories coming online. A request to sell a stronger dose of Wegovy and results expected in late July may lead experts to lift their forecasts again. Investor mood is high and the numbers look healthy, so the share could bounce 18-20% in the next few months. Big investors looking for steady profit growth may switch money here, giving the stock an extra push.
Primary drivers
- Share price is slightly above its recent average, hinting the pullback is almost done
- Applying to sell a stronger Wegovy dose in Europe could balance Canada patent issue
- Late-July results may become the third time in a row that management lifts its outlook
- Upbeat investor mood and solid finances can attract cash from cautious growth funds
How it played out
NVO: target was not reached
Lyra published NVO on 2025-07-10 at 68.91. The thesis expected 18% growth toward 80.41. It pointed to a 12% dip, growth in Ozempic and Wegovy, new factories, a stronger Wegovy dose request in Europe, late-July results, upbeat investor mood, and solid finances.
Inside the window from 2025-07-10 to 2025-10-08, the stock peaked at 71 on 2025-07-25. That was a 3% gain, but it stayed below the 80.41 target. It ended at 59.61. The thesis missed.
What happened during the window
On 2025-07-29, Novo Nordisk named Maziar Mike Doustdar as president and chief executive officer and lowered its financial growth outlook. On 2025-09-18, the company reported trial results for a daily oral Wegovy version, and shares rose that day.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.